The World Health Organization published blueprints for urgently needed antibiotics targeting drug-resistant infections, while CARB-X awarded $1.2 million for novel antibiotic research and the FDA issued guidance on antibiotic duration limits in livestock.
The FDA has granted breakthrough device designation to two rapid diagnostic assays from NG Biotech and Hardy Diagnostics targeting Candida auris and carbapenem-resistant Acinetobacter baumannii, both identified as global health priorities by the WHO.
Researchers at Stanford and Harvard are developing nasal spray vaccines offering broad protection against respiratory infections, with early animal and phase 1 human trials showing safety and potential efficacy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06670872 |
A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia |
NOT_YET_RECRUITING | |
| NCT06282835 |
Eravacycline Combination Therapy for MRAB |
RECRUITING | |
| NCT06173440 |
Management of an Imipenem-resistant Acinetobacter Baumannii Alert in a French University Hospital |
RECRUITING |
